Novel Therapeutic Modalities Synthesis

Novel Therapeutic Modalities Synthesis

Overview

This synthesis provides a comprehensive analysis of novel therapeutic modalities transforming neurodegenerative disease drug development. We examine five major modality classes: (1) Targeted Protein Degradation (PROTACs, Molecular Glues), (2) Antisense Oligonucleotides (ASOs), (3) Gene Therapy (AAV, CRISPR), (4) Cell Therapy (iPSC, MSC), and (5) Emerging Modalities (RNAi, peptide therapeutics). Each modality offers distinct advantages and challenges for CNS drug delivery and therapeutic efficacy.

This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026), and [Investment-Evidence Convergence Analysis](/mechanisms/investment-evidence-convergence-analysis) by providing deep technical analysis of specific therapeutic modalities.

Therapeutic Modality Comparison Matrix

Novel Therapeutic Modalities Synthesis

Overview

This synthesis provides a comprehensive analysis of novel therapeutic modalities transforming neurodegenerative disease drug development. We examine five major modality classes: (1) Targeted Protein Degradation (PROTACs, Molecular Glues), (2) Antisense Oligonucleotides (ASOs), (3) Gene Therapy (AAV, CRISPR), (4) Cell Therapy (iPSC, MSC), and (5) Emerging Modalities (RNAi, peptide therapeutics). Each modality offers distinct advantages and challenges for CNS drug delivery and therapeutic efficacy.

This synthesis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026), and [Investment-Evidence Convergence Analysis](/mechanisms/investment-evidence-convergence-analysis) by providing deep technical analysis of specific therapeutic modalities.

Therapeutic Modality Comparison Matrix

| Modality | Mechanism | CNS Delivery Challenge | Development Stage | Key Advantages | Key Limitations |
|----------|-----------|------------------------|-------------------|-----------------|-----------------|
| PROTACs | Induce target degradation via E3 ligase | HIGH — requires BBB penetration | Preclinical-Phase 1 | Catalytic activity, undruggable targets | Complex PK, off-target risk |
| Molecular Glues | Induce protein-protein interactions | MODERATE | Preclinical-Phase 1 | Simpler than PROTACs | Limited target scope |
| ASOs | Modulate RNA splicing/translation | MODERATE — intrathecal/nasal | Approved-Phase 3 | Genetic precision, allele-specific | Repeat dosing, immune response |
| Gene Therapy (AAV) | Deliver therapeutic gene | HIGH — BBB crossing | Phase 1-3 | Long-term expression | Limited cargo size, immune pre-existing |
| CRISPR Gene Editing | Direct genome modification | VERY HIGH | Preclinical-Phase 1 | Permanent correction | Delivery, off-target editing |
| iPSC Cell Therapy | Cell replacement | VERY HIGH | Phase 1-2 | Dopamine neuron replacement | Tumor risk, immune rejection |
| MSC Therapy | Paracrine modulation | MODERATE | Phase 1-2 | Immunomodulatory | Variable efficacy |

1. Targeted Protein Degradation (TPD)

1.1 PROTACs (PROteolysis TArgeting Chimeras)

PROTACs are bifunctional molecules consisting of a target-binding ligand connected to an E3 ubiquitin ligase recruiter via a linker. This architecture enables catalytic degradation of disease-causing proteins at sub-stoichiometric concentrations[@dale2022].

Mechanism of Action

Therapeutic Targets in Neurodegeneration

| Target | Disease | Development Stage | degron Ligand | Partner/Company |
|--------|---------|-------------------|---------------|-----------------|
| Tau | AD/PSP | Preclinical | Tau ligand + CRBN | Arvinas, BMS |
| Alpha-Synuclein | PD | Preclinical | Alpha-syn ligand + VHL | Prothena, BMS |
| TDP-43 | ALS/FTD | Preclinical | TDP-43 ligand + CRBN | Academia |
| Huntingtin | HD | Preclinical | PolyQ ligand + VHL | CHDI Foundation |
| SOD1 | ALS | Preclinical | SOD1 ligand + VHL | Wave Life Sciences |

Key Advantages

• Catalytic activity: Single PROTAC molecule can degrade multiple target proteins
• Undruggable target access: Can target proteins lacking druggable pockets
• Potential for lower dosing: Substoichiometric activity may reduce systemic exposure

Key Challenges

• BBB penetration: Molecular weight >500 Da required, typically 600-1000 Da
• Linker optimization: Length and composition affect efficacy and PK
• Off-target degradation: Need careful selectivity assessment

1.2 Molecular Glues

Molecular glues are small molecules that induce proximity between a target protein and an E3 ligase, triggering degradation without requiring bifunctional architecture[@mayorruiz2024].

Clinical Candidates

| Compound | Target | Disease | Stage | Company |
|----------|--------|---------|-------|---------|
| Iberdomide | CRBN | Multiple myeloma | Approved | Bristol Myers |
| CC-885 | GSPT1 | AML | Phase 1 | Bristol Myers |
| BMS-986463 | Tau | AD | Preclinical | Bristol Myers |

Mechanism Comparison

1.3 Autophagy-Targeting Chimeras (AUTACs) and Lysosomal TPD

AUTACs recruit cargo to autophagosomes via autophagy receptor binding, enabling degradation of larger protein complexes and organelles.

| Modality | Target Size | Delivery Challenge | Status |
|----------|-------------|---------------------|--------|
| PROTAC | ~50 kDa | High (BBB) | Preclinical |
| AUTAC | >100 kDa | Very High | Preclinical |
| Lysosome Tether | >200 kDa | Very High | Preclinical |

2. Antisense Oligonucleotides (ASOs)

ASOs are single-stranded DNA analogs (typically 12-25 nucleotides) that modulate RNA splicing, translation, or degradation through Watson-Crick base pairing.

2.1 Approved ASO Therapies for Neurodegeneration

| Drug | Target | Disease | Administration | Approval Year |
|------|--------|---------|----------------|---------------|
| Tofersen | SOD1 | ALS | Intrathecal | 2024[@miller2023] |
| Milasen | MFSD8 | Batten disease | Intrathecal | 2018 (N=1) |
| Apicalersen | C9orf72 | ALS/FTD | Intrathecal | Phase 3 |

2.2 ASO Mechanism of Action

2.3 Pipeline for Neurodegeneration

| Target | Disease | ASO Design | Stage | Company |
|--------|---------|------------|-------|---------|
| MAPT | AD/PSP | Splicing modulator | Phase 1-2 | Ionis, Biogen |
| LRRK2 | PD | Allele-specific | Preclinical | Ionis |
| GBA | PD | Knockdown | Preclinical | Ionis |
| HTT | HD | ASO | Phase 1-2 | Roche, Ionis |
| ATXN2 | ALS | Splicing | Phase 1 | Biogen |

2.4 CNS Delivery Strategies

| Strategy | Route | Advantage | Limitation |
|----------|-------|-----------|------------|
| Intrathecal | Lumbar puncture | Direct CSF access | Invasive, repeated |
| Intranasal | Nasal spray | Non-invasive | Limited distribution |
| Conjugate | IV + targeting | Systemic | BBB penetration |
| AAV-vectored | Gene-delivered | Long-term | Immunogenicity |

3. Gene Therapy

3.1 AAV Gene Therapy

Recombinant AAV vectors deliver therapeutic genes to neurons, enabling long-term protein expression without genomic integration[@banks2024].

Clinical Pipeline

| Gene | Disease | Vector | Route | Stage | Company |
|------|---------|--------|-------|-------|---------|
| AADC | PD | AAV2 | Intraparenchymal | Phase 2-3 | Roche, UCSD |
| GBA | PD | AAV9 | Intrathecal | Phase 1 | Prevail, Eli Lilly |
| LRRK2-ASO | PD | AAV | Intrathecal | Preclinical | Ionis |
| NFT | AD | AAV | IV | Preclinical | Cerevel |
| CLN2 | Batten | AAV9 | Intrathecal | Approved | BioMarin |

AAV Serotype Comparison for CNS

3.2 CRISPR Gene Editing

CRISPR-Cas systems enable precise genome editing, offering potential for permanent correction of disease-causing mutations.

| Approach | Mechanism | Delivery | Stage | Challenges |
|----------|-----------|----------|-------|------------|
| Knockout | Cas9 cutting | AAV, LNP | Phase 1 | Off-target |
| Knock-in | HDR | AAV, electroporation | Preclinical | Efficiency |
| Base Editing | A to I, C to T conversion | AAV, LNP | Preclinical | Delivery |
| Prime Editing | All 12 conversions | AAV, LNP | Preclinical | Packaging |

Pipeline

| Target | Disease | Approach | Company | Stage |
|--------|---------|----------|---------|-------|
| SOD1 | ALS | Knockout | Excision, Univ. Michigan | Preclinical |
| HTT | HD | Knockdown | CRISPR Tx, Wave | Preclinical |
| GBA | PD | Knock-in | Intellia | Preclinical |
| LRRK2 | PD | Knockout | Caribou | Preclinical |

4. Cell Therapy

4.1 iPSC-Derived Cell Therapy

Induced pluripotent stem cells (iPSCs) can be differentiated into dopaminergic neurons, motor neurons, or glial cells for transplantation[@kumar2024].

Clinical Trials

| Trial | Cell Type | Disease | Stage | Outcome |
|-------|-----------|--------|-------|---------|
| NCT02445612 | iDA | PD | Phase 1 | Safety OK, motor improvement |
| NCT04654056 | iMN | ALS | Phase 1 | Enrolling |
| NCT04798534 | iDA | PD | Phase 2 | Active |

4.2 Mesenchymal Stem Cell (MSC) Therapy

MSCs exert therapeutic effects through paracrine signaling, immunomodulation, and trophic factor secretion.

| Mechanism | Effect | Delivery |
|-----------|--------|----------|
| Paracrine | BDNF, GDNF secretion | IV, intrathecal |
| Immunomodulation | Tregs, anti-inflammatory | IV |
| Metabolic | Mitochondrial transfer | IV |

Clinical Status

| Trial | Cell Source | Disease | Route | Stage |
|-------|-------------|---------|-------|-------|
| NCT03795967 | BM-MSC | PD | IV | Phase 1-2 |
| NCT03301420 | UC-MSC | AD | IV | Phase 1-2 |
| NCT04545103 | BM-MSC | ALS | IV | Phase 2 |

5. Emerging Modalities

5.1 RNA Interference (RNAi)

| Modality | Mechanism | Advantages | Challenges |
|----------|-----------|------------|------------|
| siRNA | mRNA cleavage | Potent, specific | Delivery, off-target |
| miRNA | Multiple targets | Natural regulation | Specificity |
| shRNA | Nuclear processing | Long-term | Delivery |

5.2 Peptide Therapeutics

| Target | Peptide | Mechanism | Stage |
|--------|---------|-----------|-------|
| Alpha-Synuclein | ELAM | Aggregation blocker | Preclinical |
| Tau | Peptide-Tau | Phosphorylation mod | Preclinical |
| BACE | Pep2-BACE | Enzyme inhibitor | Preclinical |

5.3 Brain-Targeted Nanotechnology

| Platform | Cargo | BBB Strategy | Stage |
|----------|-------|-------------|-------|
| Lipid nanoparticles | mRNA | ApoE-mediated | Phase 1 |
| Polymeric NPs | siRNA | Receptor-mediated | Preclinical |
| Exosomes | miRNA | Natural crossing | Preclinical |

6. Cross-Disease Modality Prioritization

Alzheimer's Disease

| Modality | Priority Score | Rationale |
|----------|---------------|-----------|
| GLP-1 Agonist | 9.8 | Phase 3 readouts |
| TREM2 Agonist | 9.5 | Mechanism validation |
| TPD (Tau) | 7.5 | Undruggable target |
| ASO (APOE4) | 7.0 | Genetic precision |
| Gene Therapy (NFT) | 6.5 | Novel target |

Parkinson's Disease

| Modality | Priority Score | Rationale |
|----------|---------------|-----------|
| Alpha-Syn Immunotherapy | 9.3 | Phase 2b data |
| LRRK2 Inhibitor | 8.9 | Genetic linkage |
| GBA Restoration | 8.7 | Chaperone + gene |
| Gene Therapy (AADC) | 8.5 | Approved in Japan |
| iPSC DA Neurons | 7.0 | Cell replacement |

ALS

| Modality | Priority Score | Rationale |
|----------|---------------|-----------|
| ASO (C9orf72) | 9.0 | Most common genetic |
| Tofersen (SOD1) | 8.8 | Approved |
| Gene Therapy | 8.5 | Permanent correction |
| iPSC Motor Neurons | 6.5 | Cell replacement |

7. Knowledge Gaps and Research Priorities

Critical Gaps

Research Priorities

| Priority | Modality | Research Need | Impact |
|----------|----------|---------------|--------|
| HIGH | TPD | Brain-penetrant PROTACs | Enable novel targets |
| HIGH | ASO | Non-invasive delivery | Patient access |
| MEDIUM | Gene Therapy | Off-target assessment | Safety |
| MEDIUM | Cell Therapy | Tumor risk monitoring | Safety |
| MEDIUM | All | CNS pharmacodynamic markers | Development |

8. Synthesis with Other Wiki Pages

This synthesis connects to multiple existing wiki pages:

Therapeutic Rankings

• [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings) — provides evidence scores for these modalities
• [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026) — pipeline updates

Gene-Specific Pages

• [SOD1 ALS Causal Chain](/mechanisms/sod1-superoxide-dismutase-als-causal-chain) — Tofersen mechanism
• [LRRK2 Pathway](/mechanisms/lrrk2-pathway-parkinsons) — LRRK2 inhibitor development
• [GBA GCase PD Causal Chain](/mechanisms/gba1-gcase-lysosome-pd-causal-chain) — gene therapy targets

Technology Pages

• [CRISPR Gene Editing](/technologies/crispr-gene-editing) — genome editing technology
• [AAV Vectors](/technologies/aav-vectors) — gene therapy delivery
• [iPSC Disease Models](/technologies/ipsc-disease-models) — cell therapy source

Investment Pages

• [Investment-Evidence Convergence](/mechanisms/investment-evidence-convergence-analysis) — funding alignment
• [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis) — biotech investment trends

9. Evidence Scores

| Modality Category | Genetic Evidence | Mechanism Validation | Therapeutic Development | Clinical Evidence | Overall |
|------------------|-----------------|---------------------|------------------------|-------------------|---------|
| TPD | 8.5 | 8.0 | 6.5 | 5.0 | 7.0 |
| ASO | 9.5 | 9.0 | 8.5 | 8.0 | 8.75 |
| Gene Therapy | 8.5 | 8.5 | 8.0 | 7.5 | 8.0 |
| Cell Therapy | 7.0 | 7.5 | 7.0 | 6.5 | 7.0 |

10. Summary

Novel therapeutic modalities represent a transformative shift in neurodegenerative disease drug development. ASO therapy has achieved the first FDA approval in ALS (Tofersen), validating the genetic precision approach. Gene therapy shows promise for monogenic disorders, while TPD offers a new paradigm for previously undruggable targets. Cell therapy remains promising but faces challenges in safety and delivery. The convergence of multiple modalities creates opportunities for combination approaches targeting different aspects of neurodegeneration simultaneously.

References